Stepped-care cognitive behaviour therapy program for treating cancer-related fatigue: protocol for a feasibility study.
CBT
Cancer
Cognitive behaviour therapy
Fatigue
Psychological
Stepped-care
Survivor
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
27 May 2022
27 May 2022
Historique:
received:
11
11
2021
accepted:
04
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
Cancer-related fatigue (CRF) is a commonly experienced and often debilitating side effect of cancer treatment that can persist for years after treatment completion. The benefits of cognitive behaviour therapy (CBT) for CRF are well established; however, these interventions are typically not included in standard clinical care. Traditional CBT is resource-intensive, limiting implementation in hospital settings. Stepped-care approaches can offer benefits to more people, using the same personnel as traditional models. This is a single-arm feasibility study. Fifty people with a cancer diagnosis, at least 12 weeks post-treatment or on long-term maintenance treatment, with persistent CRF that is affecting daily activities, will enrol in a stepped-care CBT program. The stepped-care program involves two steps. Step 1: All participants begin with a 5-week supported self-management CBT progam targeting fatigue. Step 2: If fatigue remains severe or has changed less than the minimal clinically important difference on the fatigue measure after step 1, participants will be offered four sessions of therapist-directed group CBT. Participants will complete questionnaires at baseline and 6 and 10 weeks. The primary outcome is feasibility of the REFRESH program. The implementation evaluation comprises acceptability, satisfaction, appropriateness, and feasibility of the study intervention, along with administrative data including cost, processes, procedures and implementation. Secondary outcomes are changes in fatigue, quality of life and self-efficacy. The REFRESH program will be the first stepped-care CBT intervention for persistent CRF in Australia. Assessing feasibility of REFRESH is an important first step to establishing future implementation and efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer-related fatigue (CRF) is a commonly experienced and often debilitating side effect of cancer treatment that can persist for years after treatment completion. The benefits of cognitive behaviour therapy (CBT) for CRF are well established; however, these interventions are typically not included in standard clinical care. Traditional CBT is resource-intensive, limiting implementation in hospital settings. Stepped-care approaches can offer benefits to more people, using the same personnel as traditional models.
METHOD/DESIGN
METHODS
This is a single-arm feasibility study. Fifty people with a cancer diagnosis, at least 12 weeks post-treatment or on long-term maintenance treatment, with persistent CRF that is affecting daily activities, will enrol in a stepped-care CBT program.
INTERVENTION
METHODS
The stepped-care program involves two steps. Step 1: All participants begin with a 5-week supported self-management CBT progam targeting fatigue. Step 2: If fatigue remains severe or has changed less than the minimal clinically important difference on the fatigue measure after step 1, participants will be offered four sessions of therapist-directed group CBT.
MEASURES
METHODS
Participants will complete questionnaires at baseline and 6 and 10 weeks. The primary outcome is feasibility of the REFRESH program. The implementation evaluation comprises acceptability, satisfaction, appropriateness, and feasibility of the study intervention, along with administrative data including cost, processes, procedures and implementation. Secondary outcomes are changes in fatigue, quality of life and self-efficacy.
CONCLUSION
CONCLUSIONS
The REFRESH program will be the first stepped-care CBT intervention for persistent CRF in Australia. Assessing feasibility of REFRESH is an important first step to establishing future implementation and efficacy.
Identifiants
pubmed: 35624497
doi: 10.1186/s40814-022-01062-8
pii: 10.1186/s40814-022-01062-8
pmc: PMC9135989
doi:
Types de publication
Journal Article
Langues
eng
Pagination
112Subventions
Organisme : Impact Philanthropy
ID : IPAP2020/1586
Informations de copyright
© 2022. The Author(s).
Références
J Psychosom Res. 2020 Jul;134:110127
pubmed: 32428784
J Clin Oncol. 2000 Feb;18(4):743-53
pubmed: 10673515
J Clin Oncol. 2001 Jul 15;19(14):3385-91
pubmed: 11454886
Implement Sci. 2017 Aug 29;12(1):108
pubmed: 28851459
Psychosomatics. 2009 Sep-Oct;50(5):440-7
pubmed: 19855028
Scand J Occup Ther. 2020 Oct;27(7):507-516
pubmed: 31729272
J Palliat Med. 2007 Oct;10(5):1068-75
pubmed: 17985963
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Syst Rev. 2019 Dec 13;8(1):324
pubmed: 31836007
Asian Pac J Cancer Prev. 2015;16(3):1063-7
pubmed: 25735332
J Cancer Surviv. 2012 Mar;6(1):11-9
pubmed: 22160661
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
Semin Hematol. 1997 Jul;34(3 Suppl 2):13-9
pubmed: 9253779
Ann Behav Med. 2022 Feb 11;56(2):137-145
pubmed: 33991085
JAMA Oncol. 2017 Jul 01;3(7):961-968
pubmed: 28253393
BMC Cancer. 2015 Oct 23;15:765
pubmed: 26500019
Nat Rev Clin Oncol. 2014 Oct;11(10):597-609
pubmed: 25113839
Cancer. 2002 Jan 15;94(2):528-38
pubmed: 11900238
Behav Ther. 2007 Jun;38(2):179-91
pubmed: 17499084
Cancer Med. 2020 Nov;9(21):8053-8061
pubmed: 32893501
Med Care. 1989 Mar;27(3 Suppl):S178-89
pubmed: 2646488
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Am J Prev Med. 2009 May;36(5):452-7
pubmed: 19362699
J Patient Rep Outcomes. 2021 Mar 11;5(1):27
pubmed: 33709202
J Clin Oncol. 2006 Oct 20;24(30):4882-7
pubmed: 17050873
BMC Med Res Methodol. 2013 Aug 20;13:104
pubmed: 23961782
Cancer Nurs. 2011 May-Jun;34(3):167-75
pubmed: 21512344
Eval Program Plann. 1982;5(3):233-7
pubmed: 10259963
Pilot Feasibility Stud. 2021 Feb 3;7(1):40
pubmed: 33536076
CA Cancer J Clin. 2015 May-Jun;65(3):190-211
pubmed: 25760293